الإحصائيات الأساسية
| LEI | 529900DOOGH8WKB2WL85 |
| CIK | 1084201 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Sinovac Biotech, Ltd.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| July 11, 2025 |
Exhibit 99.1 Newly Elected Directors of Sinovac Hold the First Board Meeting Mr. Andrew Y. Yan elected Chairman of the Board New Board Unanimously Resolved to Explore Future Dividend Plans, Conduct Search for New Auditor for Resuming NASDAQ Trading, and Restore Stable Operations of the Company, Amongst Other Things BEIJING, July 10, 2025 – Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company |
|
| July 11, 2025 |
6-K 1 ea0248567-6ksinovac.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 100085, People’s Rep |
|
| July 10, 2025 |
Exhibit 99.2 SINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend Payment Special cash dividend is being paid to valid common shareholders who owned SINOVAC as of the close of business on July 7, 2025 Board will continue to prioritize dividend distributions according to its previously announced policy For any questions about the dividend payment process, sharehold |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| July 10, 2025 |
Exhibit 99.1 SINOVAC Board of Directors Announces Adjournment of Special Meeting of Shareholders Until Appropriate Court Can Make a Final Decision on the Validity of the PIPE Shares On July 7 Antigua Court restricted PIPE shares from voting in Special Shareholder Meeting, but Eastern Caribbean Court of Appeal granted a temporary stay of the injunction shortly before Special Meeting 2018 PIPE trans |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| July 10, 2025 |
Exhibit 99.1 SINOVAC Board of Directors Strongly Denounces Deceptive and Illegal Claims by SAIF and the Imposter Former Board Special Meeting was validly adjourned until the appropriate court can make a final decision on the validity of the PIPE shares SAIF’s “announcement” about voting results demonstrates blatant disregard for the law and the Company’s bylaws and a repeated pattern of self-servi |
|
| July 8, 2025 |
Exhibit 99.1 Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in Place ISS states, “[T]he [current] board appears to be working to pay SVA shareholders their fair share of dividends, and to resume trading of the company's shares, which are the two most pressing issues currently facing SVA shareholders.” SINOVAC’s Boar |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| July 8, 2025 |
Exhibit 99.3 Final Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card “AGAINST” Misguided Proposals 1 and 2 SINOVAC’s Board of Directors encourages shareholders to follow recommendations of leading independent proxy advisory firms ISS and Glass Lewis and VOTE to KEEP the Current Board in Place VOTE as soon as possible – only the latest-dated vote will count Due to limited venue capacit |
|
| July 8, 2025 |
Exhibit 99.2 Federal Court in Massachusetts Denies Vivo Capital’s Petition for Relief on SINOVAC Court denies Vivo Capital's petition for relief relating to shareholder votes and corporate governance, clearing another legal hurdle for distribution of the US$55.00 per common share special cash dividend Marks fourth unsuccessful legal attempt in deceptive and disparaging campaign by Advantech/Prime |
|
| July 2, 2025 |
Exhibit 99.1 Leading Independent Proxy Advisory Firm Glass Lewis Recommends SINOVAC Shareholders Vote to Keep the Current Board in Place Glass Lewis concludes, “[T]he current board has demonstrated credible progress in restoring governance stability and operational normalcy. [...] The Dissident Group’s proposals, by contrast, rest on an inconsistent platform, rely on individuals linked to the gove |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| June 30, 2025 |
Exhibit 99.2 SINOVAC Board of Directors Prevails Against Advantech/Prime’s Lawsuit in Hong Kong Hong Kong Court denies Advantech/Prime’s petition for Interim Relief Clears another legal hurdle for distribution of the US$55.00 per common share special cash dividend declared by the current SINOVAC Board to be paid on or about July 7, 2025 BEIJING, June 28, 2025 – The Board of Directors of SINOVAC Bi |
|
| June 30, 2025 |
Exhibit 99.1 SINOVAC Board of Directors Urges Shareholders to Vote the WHITE Proxy Card “AGAINST” the Misguided Proposals to Remove SINOVAC’s Current Board Reaffirms Commitment to Declaring Dividends and New Dividend Policy Underscores Pledge to Work with NASDAQ Toward Resuming Trading Continues to Diligently Defend Against the Dissenting Investor Group’s Multi-Jurisdictional Legal Tactics to Bloc |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| June 30, 2025 |
Exhibit 99.3 SINOVAC Board of Directors Prevails Against Advantech/Prime’s New York Lawsuit New York Court Denies Advantech/Prime’s Petition for Emergency Injunctive Relief Clears Legal Hurdle for Dividend Paying Agent to Payout the Special Cash Dividend of US$55.00 Per Common Share on July 7, 2025 BEIJING, June 21, 2025 – SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading |
|
| June 25, 2025 |
Exhibit 99.2 Restore Fairness and Deliver Value to All SINOVAC Shareholders Official communication from the Sinovac Biotech Ltd. Board of Directors, June 2025 | 2 Safe Harbor Statement This presentation and related materials contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigati |
|
| June 25, 2025 |
Exhibit 99.1 SINOVAC Board of Directors Files Investor Presentation Outlining Decisive Actions to Protect Shareholder Interests Highlights bold steps to restore fairness to SINOVAC’s common shareholders and deliver long-term value creation Urges shareholders to VOTE the WHITE proxy card “AGAINST” the misguided proposals to remove SINOVAC’s Board and appoint the Reconstituted Imposter Former Board |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| June 20, 2025 |
Exhibit 99.1 SINOVAC Board of Directors Files Definitive Proxy Materials Files definitive proxy statement and mails letter to shareholders Urges shareholders to VOTE the WHITE proxy card and vote “AGAINST” the misguided proposals to remove SINOVAC’s Board and appoint the Reconstituted Imposter Former Board Slate BEIJING, June 19, 2025 – The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| June 18, 2025 |
SINOVAC Announces New Board Member Exhibit 99.2 SINOVAC Announces New Board Member BEIJING – Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the “Board”) and a member of the Audit Committee, Compensation Committee and the Corporate Governance an |
|
| June 18, 2025 |
OUR BOARD RECOMMENDS THAT YOU VOTE “AGAINST” PROPOSAL 1 AND PROPOSAL 2. Exhibit 99.1 Chairman’s Message Dear Shareholders, I would like to inform you that a 2025 Special Meeting (the “Special Meeting”) of Shareholders of Sinovac Biotech Ltd. will be held on Tuesday, 8 July 2025 at 8:00 p.m. Atlantic Standard Time (Wednesday, 9 July 2025 at 8:00 a.m. China Standard Time). The meeting will be held at Stapleton Chambers Inc., Suite No. 2, Stapleton House, Stapleton Lane, |
|
| June 18, 2025 |
Exhibit 99.1 SINOVAC Board of Directors Provides Update on Special Dividend Payment and Commitment to Delivering Value to All Shareholders Accelerates payment of previously announced special cash dividend of US$55.00 per common share Decides to declare second special cash dividend of US$19.00 per common share Intends to declare third special cash dividend between US$20.00 – US$50.00 per common sha |
|
| June 18, 2025 |
Exhibit 99.2 V OTE BY T ELEPHONE Please have your WHITE proxy card available when you call the toll-free number 1-888-693-8683 using a touch-tone telephone and follow the simple directions that will be presented to you. V OTE BY I NTERNET Please have your WHITE proxy card available when you access the website www.cesvote.com and follow the simple directions that will be presented to you. V OTE BY |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| May 23, 2025 |
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2024 Annual Report Exhibit 99.1 SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2024 Annual Report BEIJING – Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 16, 2025 (the “Notification Letter”) from Nasdaq Listing Qualifications (“Nasdaq”), stating that the Compan |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| May 20, 2025 |
SINOVAC BIOTECH LTD. NOTICE OF SPECIAL MEETING OF SHAREHOLDERS Exhibit 99.1 SINOVAC BIOTECH LTD. NOTICE OF SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that a Special Meeting of Shareholders of Sinovac Biotech Ltd. (the “Company”) will be held on Tuesday, 8 July 2025 at 8:00 p.m. Atlantic Standard Time (Wednesday, 9 July 2025 at 8:00 a.m. China Standard Time) pursuant to a requisition made by Cede & Co., as the registered holder of 10,780,820 common |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| April 30, 2025 |
Exhibit 99.2 SINOVAC Board Issues Letter to Shareholders to Set the Record Straight on the Hostile Actions and False Claims by Vivo Capital April 29, 2025 - BEIJING – Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) issued a public letter to shareholders in response |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| April 30, 2025 |
SINOVAC Announces Record and Distribution Dates for Special Cash Dividend Exhibit 99.1 SINOVAC Announces Record and Distribution Dates for Special Cash Dividend BEIJING – Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that a special dividend of US$55.00 per common share, as previously announced on April 1, 2025, will be paid in cash to valid holders of SINOVAC’s common shares as |
|
| April 29, 2025 |
SEC FILE NUMBER 001-32371 CUSIP NUMBER P8696W104 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| April 21, 2025 |
Securities and Exchange Commission Exhibit 16.1 Grant Thornton Zhitong Certified Public Accountants LLP 15/F Scitech Place Jianguomen Wai Avenue Beijing 100004, China T +86 10 8566 5588 F +86 10 8566 5050 www.grantthornton.cn Securities and Exchange Commission We have read Sinovac Biotech Ltd.’s statements included in the section titled “Changes in Registrant’s Certifying Accountant; Non-Reliance on Previously Issued Audit and Inte |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| April 1, 2025 |
SINOVAC Announces Decision to Declare Cash Dividend Exhibit 99.1 SINOVAC Announces Decision to Declare Cash Dividend BEIJING – Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company’s board of directors (the “Board”) has decided to declare a special cash dividend of US$55.00 per common share (the “Dividend”). The Board expects to fund the Dividend |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| March 31, 2025 |
SINOVAC Announces New Board Member and Chairman of the Audit Committee Exhibit 99.1 SINOVAC Announces New Board Member and Chairman of the Audit Committee BEIJING – Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) has appointed Sven H. Borho, CFA, as director to the Board to fill in a vacancy created by a recent resignation. As a qualifi |
|
| February 28, 2025 |
SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order Exhibit 99.1 SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order BEIJING – Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) from the Privy Council following the previously announced Privy Council Judgment (th |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| February 19, 2025 |
SVA / Sinovac Biotech, Ltd. / SAIF Partners IV L.P. - EXHIBIT 7.09 Exhibit 7.09 AMENDMENT NO.7 TO THE INVESTMENT AGREEMENT This AMENDMENT NO.7 TO THE INVESTMENT AGREEMENT (this “Amendment”) dated as of February 18, 2025 is made by and between (i) SAIF PARTNERS IV L.P., an exempted limited partnership registered and existing under the Laws of the Cayman Islands (the “Seller”) and (ii) YZ Healthcare L.P., an exempted partnership established under the Laws of the Ca |
|
| January 16, 2025 |
SINOVAC Issues Statement Regarding Privy Council Judgment Exhibit 99.1 SINOVAC Issues Statement Regarding Privy Council Judgment BEIJING – Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Judicial Committee of the Privy Council in London, England, has ruled that the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was |
|
| January 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| September 12, 2024 |
SVA / Sinovac Biotech, Ltd. / SAIF Partners IV L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.13)* SINOVAC BIOTECH LTD. (Name of Issuer) Common Shares (Title of Class of Securities) P8696W104 (CUSIP Number) Andrew Y. Yan c/o SAIF Advisors Limited Suite 2516-2520, Two Pacific Place 88 Queensway Hong Kong +852 2918-2200 (Name, Address and Telephone Numb |
|
| September 12, 2024 |
AMENDMENT NO.6 TO THE INVESTMENT AGREEMENT EX-7.08 2 tm2423909d1ex7-08.htm EXHIBIT 7.08 Exhibit 7.08 AMENDMENT NO.6 TO THE INVESTMENT AGREEMENT This AMENDMENT NO.6 TO THE INVESTMENT AGREEMENT (this “Amendment”) dated as of September 12, 2024 is made by and between (i) SAIF PARTNERS IV L.P., an exempted limited partnership registered and existing under the Laws of the Cayman Islands (the “Seller”) and (ii) YZ Healthcare L.P., an exempted pa |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| August 16, 2024 |
SINOVAC Reports Unaudited First Half of 2024 Financial Results Exhibit 99.1 SINOVAC Reports Unaudited First Half of 2024 Financial Results BEIJING, China, August 16, 2024 /Business Wire/ - Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2024. First Half of 2024 Financial Summary · Sales for the six month |
|
| June 17, 2024 |
SVA / Sinovac Biotech, Ltd. / SAIF Partners IV L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm2417413d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 12)* SINOVAC BIOTECH LTD. (Name of Issuer) Common Shares (Title of Class of Securities) P8696W104 (CUSIP Number) Andrew Y. Yan c/o SAIF Advisors Limited Suite 2516-2520, Two Pacific Place 88 Queensway Hong Kong +852 |
|
| June 17, 2024 |
AMENDMENT NO.5 TO THE INVESTMENT AGREEMENT EX-7.07 2 tm2417413d1ex7-07.htm EXHIBIT 7.07 Exhibit 7.07 AMENDMENT NO.5 TO THE INVESTMENT AGREEMENT This AMENDMENT NO.5 TO THE INVESTMENT AGREEMENT (this “Amendment”) dated as of June 13, 2024 is made by and between (i) SAIF PARTNERS IV L.P., an exempted limited partnership registered and existing under the Laws of the Cayman Islands (the “Seller”) and (ii) YZ Healthcare L.P., an exempted partner |
|
| April 30, 2024 |
Exhibit 99.1 SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F BEIJING, China, April 29, 2024 /Business Wire/ - Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| April 29, 2024 |
Exhibit 13.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Sinovac Biotech Ltd. (the “Company”) on Form 20-F for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Weidong Yin, Chief Executive Officer of the Company, certify, purs |
|
| April 29, 2024 |
SINOVAC BIOTECH LTD. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Exhibit 97.1 SINOVAC BIOTECH LTD. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION The Board of Directors (the “Board”) of Sinovac Biotech Ltd. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Se |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission file number: 001-32371 SINOVAC BIOTECH LTD. |
|
| April 29, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We have issued our reports dated April 29, 2024, with respect to the consolidated financial statements and internal control over financial reporting included in the Annual Report of Sinovac Biotech Ltd. on Form 20-F for the year ended December 31, 2023. We consent to the incorporation by reference of said reports in the Registra |
|
| April 29, 2024 |
Exhibit 12.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Nan Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made |
|
| April 29, 2024 |
Exhibit 12.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements m |
|
| April 29, 2024 |
Exhibit 13.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Sinovac Biotech Ltd. (the “Company”) on Form 20-F for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nan Wang, Chief Financial Officer of the Company, certify, pursuan |
|
| March 20, 2024 |
SVA / Sinovac Biotech, Ltd. / Advantech Capital L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.1)* SINOVAC BIOTECH LTD. (Name of Issuer) Common Shares, par value $0.001 per share (Title of Class of Securities) P8696W104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Sinovac Biotech Ltd. - (Name of Subject Company (Issuer)) Alternative Liquidity Index LP - (Names of Filing Person (Purchaser)) Common Stock, $0.01 par value - (Title of Class of Securi |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A Amendment No. 5 FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 SINOVAC BIOTECH LTD. (Exact name of registrant as specified in its charter) Antigua, West Indies Not Applicable (State or other jurisdiction (I.R.S. Employer Identification of inc |
|
| February 21, 2024 |
Sinovac Amends Shareholder Rights Plan Exhibit 99.1 Sinovac Amends Shareholder Rights Plan BEIJING, China, February 21, 2024 /Business Wire/ - Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2024 to Februar |
|
| February 21, 2024 |
Exhibit 4.1 SINOVAC BIOTECH LTD. and PACIFIC STOCK TRANSFER COMPANY as Rights Agent FIFTH AMENDMENT TO AMENDED AND RESTATED RIGHTS AGREEMENT Effective as of February 21, 2024 This Fourth Amendment (this “Amendment”) to the Amended and Restated Rights Agreement (as defined below), is between Sinovac Biotech Ltd., an Antigua and Barbuda company (the “Company”), and Pacific Stock Transfer Company (th |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| February 2, 2024 |
Assignment Form Please complete and return to: Alternative Liquidity Index LP C/O Alternative Liquidity Capital 11500 Wayzata Blvd. |
|
| February 2, 2024 |
This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Sinovac Biotech Ltd. - (Name of Subject Company (Issuer)) Alternative Liquidity Index LP - (Names of Filing Person (Purchaser)) Common Stock, $0.001 par value - (Title of Class of Secur |
|
| February 2, 2024 |
Offer to Purchase for Cash Up to 10,000,000 Shares of Sinovac Biotech Ltd. At a Price of $0.03 per share by Alternative Liquidity Index, LP CUSIP: P8696W104 Expiration Date: March 12, 2024 (unless extended) THE OFFER, THE PRORATION PERIOD, AND THE WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M., NEW YORK CITY TIME, March 12, 2024, UNLESS THE OFFER IS EXTENDED OR WITHDRAWN (AS EXTENDED OR WITHDRAWN, TH |
|
| February 2, 2024 |
Alternative Liquidity Capital Minnetonka, Minnesota, USA Alternative Liquidity Capital Minnetonka, Minnesota, USA February 1, 2024 Re: Offer to Purchase Shares of Sinovac Biotech Ltd. |
|
| January 18, 2024 |
Exhibit (a)(1) Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer Board of Directors Unanimously Recommends Sinovac Shareholders NOT Tender Shares for purchase pursuant to the Offer to Purchase BEIJING, China, January 18, 2024 /Business Wire/ - Sinovac Biotech Ltd. |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Schedule 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 SINOVAC BIOTECH LTD. |
|
| January 8, 2024 |
Offer to Purchase for Cash Up to 10,000,000 Shares of Sinovac Biotech Ltd. At a Price of $0.03 per share by Alternative Liquidity Index, LP CUSIP: P8696W104 Expiration Date: February 21, 2024 (unless extended) THE OFFER, THE PRORATION PERIOD, AND THE WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M. MIDNIGHT, NEW YORK CITY TIME, February 21, 2024, UNLESS THE OFFER IS EXTENDED OR WITHDRAWN (AS EXTENDED O |
|
| January 8, 2024 |
Assignment Form Please complete and return to: Alternative Liquidity Index LP C/O Alternative Liquidity Capital 11500 Wayzata Blvd. |
|
| January 8, 2024 |
EX-FILING FEES Calculation of Filing Fee Tables Schedule TO (Rule 14d-100) Sinovac Biotech Ltd. |
|
| January 8, 2024 |
Alternative Liquidity Capital Minnetonka, Minnesota, USA Alternative Liquidity Capital Minnetonka, Minnesota, USA January 8, 2024 Re: Offer to Purchase Shares of Sinovac Biotech Ltd. |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Sinovac Biotech Ltd. - (Name of Subject Company (Issuer)) Alternative Liquidity Index LP - (Names of Filing Person (Purchaser)) Common Stock, $0.001 par value - (Title of Class of Securities) P8696W104 - |
|
| January 8, 2024 |
This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| December 4, 2023 |
AMENDMENT NO.4 TO THE INVESTMENT AGREEMENT EX-7.06 2 tm2332066d1ex7-06.htm EXHIBIT 7.06 Exhibit 7.06 AMENDMENT NO.4 TO THE INVESTMENT AGREEMENT This AMENDMENT NO.4 TO THE INVESTMENT AGREEMENT (this “Amendment”) dated as of December 1, 2023 is made by and between (i) SAIF PARTNERS IV L.P., an exempted limited partnership registered and existing under the Laws of the Cayman Islands (the “Seller”) and (ii) YZ Healthcare L.P., an exempted part |
|
| December 4, 2023 |
SVA / Sinovac Biotech, Ltd. / SAIF Partners IV L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 11)* SINOVAC BIOTECH LTD. (Name of Issuer) Common Shares (Title of Class of Securities) P8696W104 (CUSIP Number) Andrew Y. Yan c/o SAIF Advisors Limited Suite 2516-2520, Two Pacific Place 88 Queensway Hong Kong +852 2918-2200 (Name, Address and Telephone Num |
|
| October 5, 2023 |
瑞生國際律師事務所有限法律責任合夥 18th Floor, One Exchange Square 8 Connaught Place, Central Hong Kong Tel: +852. |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Sinovac Biotech Ltd. - (Name of Subject Company (Issuer)) Alternative Liquidity Index LP - (Names of Filing Person (Purchaser)) Common Stock, $0.01 par value - (Title of Class of Securi |
|
| September 15, 2023 |
SVA / Sinovac Biotech, Ltd. / SAIF Partners IV L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* SINOVAC BIOTECH LTD. (Name of Issuer) Common Shares (Title of Class of Securities) P8696W104 (CUSIP Number) Andrew Y. Yan c/o SAIF Advisors Limited Suite 2516-2520, Two Pacific Place 88 Queensway Hong Kong +852 2918-2200 (Name, Address and Telephone Num |
|
| September 15, 2023 |
AMENDMENT NO.3 TO THE INVESTMENT AGREEMENT EX-7.05 2 tm2326228d1ex7-05.htm EXHIBIT 7.05 Exhibit 7.05 AMENDMENT NO.3 TO THE INVESTMENT AGREEMENT This AMENDMENT NO.3 TO THE INVESTMENT AGREEMENT (this “Amendment”) dated as of September 15, 2023 is made by and between (i) SAIF PARTNERS IV L.P., an exempted limited partnership registered and existing under the Laws of the Cayman Islands (the “Seller”) and (ii) YZ Healthcare L.P., an exempted pa |
|
| September 11, 2023 |
Exhibit 99.1 SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection Clinical trials will advance treatment of COVID-19 infection. September 11, 2023, Beijing, China – Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| September 5, 2023 |
Exhibit (a)(1) Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer Board of Directors Unanimously Recommends Sinovac Shareholders NOT Tender Shares for purchase pursuant to the Offer to Purchase BEIJING, China, September 5, 2023 /Business Wire/ - Sinovac Biotech Ltd. |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Schedule 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 SINOVAC BIOTECH LTD. |
|
| September 1, 2023 |
September 1, 2023 VIA EDGAR Sasha Parikh, Staff Accountant Kevin Vaughn, Senior Associate Chief Accountant Doris Stacey Gama, Attorney Jason Drory, Attorney Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| August 29, 2023 |
Sinovac Confirms Receipt of an Unsolicited Partial Tender Offer Exhibit 99.1 Sinovac Confirms Receipt of an Unsolicited Partial Tender Offer BEIJING, China, August 29, 2023 /Business Wire/ - Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, confirmed today that it is aware of an unsolicited partial tender offer from Alternative Liquidity Index LP to purchase up to a maximum of 10,000,000 |
|
| August 28, 2023 |
Sinovac Announces Change of Legal Representative of Sinovac Beijing Exhibit 99.1 Sinovac Announces Change of Legal Representative of Sinovac Beijing BEIJING, China, August 28, 2023 /Business Wire/ - Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that the Company’s subsidiary, Sinovac Biotech Co., Ltd. (“Sinovac Beijing”), has changed its legal representative to Mr. Weidong |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| August 25, 2023 |
Offer to Purchase for Cash Up to 10,000,000 Shares of Sinovac Biotech Ltd. At a Price of $0.03 per share by Alternative Liquidity Index, LP CUSIP: P8696W104 Expiration Date: September 29, 2023 (unless extended) THE OFFER, THE PRORATION PERIOD, AND THE WITHDRAWAL RIGHTS WILL EXPIRE AT 11:59 P.M. MIDNIGHT, NEW YORK CITY TIME, September 29, 2023, UNLESS THE OFFER IS EXTENDED OR WITHDRAWN (AS EXTENDED |
|
| August 25, 2023 |
This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| August 25, 2023 |
EX-FILING FEES Calculation of Filing Fee Tables Schedule TO (Rule 14d-100) Sinovac Biotech Ltd. |
|
| August 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Sinovac Biotech Ltd. - (Name of Subject Company (Issuer)) Alternative Liquidity Index LP - (Names of Filing Person (Purchaser)) Common Stock, $0.001 par value - (Title of Class of Securities) P8696W104 - |
|
| August 25, 2023 |
Assignment Form Please complete and return to: Alternative Liquidity Index LP C/O Alternative Liquidity Capital 11500 Wayzata Blvd. |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. |
|
| August 15, 2023 |
SINOVAC Reports Unaudited First Half of 2023 Financial Results Exhibit 99.1 SINOVAC Reports Unaudited First Half of 2023 Financial Results BEIJING, China, August 15, 2023 /Business Wire/ - Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2023. First Half of 2023 Financial Summary · Sales for the six month |
|
| July 10, 2023 |
瑞生國際律師事務所有限法律責任合夥 18th Floor, One Exchange Square 8 Connaught Place, Central Hong Kong Tel: +852. |
|
| May 25, 2023 |
AMENDMENT NO.2 TO THE INVESTMENT AGREEMENT Exhibit 7.04 AMENDMENT NO.2 TO THE INVESTMENT AGREEMENT This AMENDMENT NO.2 TO THE INVESTMENT AGREEMENT (this “Amendment”) dated as of May 25, 2023 is made by and between (i) SAIF PARTNERS IV L.P., an exempted limited partnership registered and existing under the Laws of the Cayman Islands (the “Seller”) and (ii) YZ Healthcare L.P., an exempted partnership established under the Laws of the Cayman |
|
| May 25, 2023 |
SVA / Sinovac Biotech, Ltd. / SAIF Partners IV L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* SINOVAC BIOTECH LTD. (Name of Issuer) Common Shares (Title of Class of Securities) P8696W104 (CUSIP Number) Andrew Y. Yan c/o SAIF Advisors Limited Suite 2516-2520, Two Pacific Place 88 Queensway Hong Kong +852 2918-2200 (Name, Address and Telephone Numb |
|
| May 1, 2023 |
CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Sinovac Biotech Ltd. (the “Company”) on Form 20-F for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Weidong Yin, Chief Executive Officer of the Company, certify, purs |
|
| May 1, 2023 |
CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Sinovac Biotech Ltd. (the “Company”) on Form 20-F for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nan Wang, Chief Financial Officer of the Company, certify, pursuan |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. |
|
| May 1, 2023 |
CEO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements m |
|
| May 1, 2023 |
CFO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Nan Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission file number: 001-32371 SINOVAC BIOTECH LTD. |
|
| May 1, 2023 |
Consent of Grant Thornton Zhitong Certified Public Accountants LLP Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We have issued our reports dated April 28, 2023, with respect to the consolidated financial statements and internal control over financial reporting included in the Annual Report of Sinovac Biotech Ltd. on Form 20-F for the year ended December 31, 2022. We consent to the incorporation by reference of said reports in the Registra |
|
| May 1, 2023 |
Consent of Marcum Bernstein & Pinchuk LLP(Formerly Marcum Bernstein & Pinchuk LLP) Exhibit 15.1 Independent Registered Public Accounting Firm’s Consent We consent to the incorporation by reference in the Registration Statement of Sinovac Biotech Ltd. on Form S-8 (FILE NO. 333-161827) and Form S-8 (FILE NO. 333-190980) of our report dated April 22, 2021, with respect to our audit of the consolidated financial statements of Sinovac Biotech Ltd. for the year ended December 31, 2020 |
|
| May 1, 2023 |
6-K 1 tm2314083d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 100085, People’s Republic of China (Address of pr |
|
| May 1, 2023 |
Exhibit 99.1 SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F BEIJING, China, May 1, 2023 /Business Wire/ - Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2022 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year end |
|
| March 15, 2023 |
SVA / Sinovac Biotech, Ltd. / SAIF Partners IV L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* SINOVAC BIOTECH LTD. (Name of Issuer) Common Shares (Title of Class of Securities) P8696W104 (CUSIP Number) Andrew Y. Yan c/o SAIF Advisors Limited Suite 2516-2520, Two Pacific Place 88 Queensway Hong Kong +852 2918-2200 (Name, Address and Telephone Numb |
|
| March 15, 2023 |
Exhibit 7.03 Execution Version AMENDMENT NO.1 TO THE INVESTMENT AGREEMENT This AMENDMENT NO.1 TO THE INVESTMENT AGREEMENT (this “Amendment”) dated as of March 15, 2023 is made by and between (i) SAIF PARTNERS IV L.P., an exempted limited partnership registered and existing under the Laws of the Cayman Islands (the “Seller”) and (ii) YZ Healthcare L.P., an exempted partnership established u |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. |
|
| February 22, 2023 |
Exhibit 4.1 SINOVAC BIOTECH LTD. and PACIFIC STOCK TRANSFER COMPANY as Rights Agent FOURTH AMENDMENT TO AMENDED AND RESTATED RIGHTS AGREEMENT Effective as of February 21, 2023 This Fourth Amendment (this “Amendment”) to the Amended and Restated Rights Agreement (as defined below), is between Sinovac Biotech Ltd., an Antigua and Barbuda company (the “Company”), and Pacific Stock Transfer Company (t |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A Amendment No. 4 FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 SINOVAC BIOTECH LTD. (Exact name of registrant as specified in its charter) Antigua, West Indies Not Applicable (State or other jurisdiction (I.R.S. Employer Identification of inc |
|
| February 22, 2023 |
Sinovac Amends Shareholder Rights Plan Exhibit 99.1 Sinovac Amends Shareholder Rights Plan BEIJING, China, February 22, 2023 /Business Wire/ - Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2023 to Februar |
|
| December 29, 2022 |
SINOVAC Reports Unaudited First Half of 2022 Financial Results EX-99.1 2 tm2233674d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 SINOVAC Reports Unaudited First Half of 2022 Financial Results BEIJING, China, December 29, 2022 /Business Wire/ - Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2022. First Half of 2 |
|
| December 29, 2022 |
6-K 1 tm2233674d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 100085, People’s Republic of China (Address of |
|
| December 12, 2022 |
Investment Agreement dated November 1, 2022 between SAIF Partner IV L.P. and YZ Healthcare L.P. Exhibit 7.02 INVESTMENT AGREEMENT This INVESTMENT AGREEMENT (this “Agreement”) dated as of November 23, 2022 is made by and between (i) SAIF PARTNERS IV L.P., an exempted limited partnership registered and existing under the Laws of the Cayman Islands (the “Seller”) and (ii) YZ Healthcare L.P., an exempted partnership established under the Laws of the Cayman Islands (the “Buyer”). The Buyer and th |
|
| December 12, 2022 |
SVA / Sinovac Biotech Ltd. / SAIF Partners IV L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* SINOVAC BIOTECH LTD. (Name of Issuer) Common Shares (Title of Class of Securities) P8696W104 (CUSIP Number) Andrew Y. Yan c/o SAIF Advisors Limited Suite 2516-2520, Two Pacific Place 88 Queensway Hong Kong +852 2918-2200 (Name, Address and Telephone Numb |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| November 4, 2022 |
SINOVAC Varicella Vaccine Prequalified by WHO Exhibit 99.1 SINOVAC Varicella Vaccine Prequalified by WHO November 4, 2022, Beijing - Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that it received prequalification from the World Health Organization (WHO) for its live attenuated varicella vaccine on November 3, 2022. This marks the first WHO prequalifi |
|
| June 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| June 9, 2022 |
SINOVAC Polio Vaccine Prequalified by WHO Exhibit 99.1 SINOVAC Polio Vaccine Prequalified by WHO BEIJING, China, June 8, 2022 -SINOVAC Biotech Ltd. (NASDAQ: SVA) (?SINOVAC? or the ?Company?), a leading provider of biopharmaceutical products in China, today announced that it received the World Health Organization (WHO) prequalification for its Poliomyelitis Vaccine (Vero Cell, Inactivated Sabin strains) (?sIPV?) on June 2, 2022. The vaccin |
|
| May 6, 2022 |
SINOVAC Updates the Status Under Holding Foreign Companies Accountable Act Exhibit 99.1 SINOVAC Updates the Status Under Holding Foreign Companies Accountable Act BEIJING, China, May 6, 2022 - Sinovac Biotech Ltd. (?SINOVAC? or the ?Company?) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, is aware that the Company has been identified by the United States Securities and Exchange Commission (?SEC?) under the Holding Foreign Companies Accountable |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| May 2, 2022 |
6-K 1 tm2214015d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 100085, People’s Republic of China (Address o |
|
| May 2, 2022 |
Exhibit 99.1 SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F BEIJING, China, April 29, 2022 /Business Wire/ - Sinovac Biotech Ltd. (NASDAQ: SVA) (?SINOVAC? or the ?Company?), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year |
|
| April 29, 2022 |
Letter dated as of April 29, 2022 from Marcum Bernstein & Pinchuk LLP EX-15.3 9 sva-ex1531110.htm EX-15.3 Exhibit 15.3 April 29, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Commissioners: We have read Item 16F of the Form 20-F for the year ended December 31, 2021 dated April 29, 2022 of Sinovac Biotech Ltd. and are in agreement with the statements contained therein concerning Marcum Bernstein & Pinchuk LLP. We have no basis to a |
|
| April 29, 2022 |
Consent of Marcum Bernstein & Pinchuk LLP Exhibit 15.1 Independent Registered Public Accounting Firm’s Consent We consent to the incorporation by reference in the Registration Statement of Sinovac Biotech Ltd. on Form S-8 (FILE NO. 333-161827) and Form S-8 (FILE NO. 333-190980) of our report dated April 22, 2021, with respect to our audits of the consolidated financial statements of Sinovac Biotech Ltd. as of December 31, 2020 and for the |
|
| April 29, 2022 |
CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Sinovac Biotech Ltd. (the “Company”) on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Weidong Yin, Chief Executive Officer of the Company, certify, purs |
|
| April 29, 2022 |
CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Sinovac Biotech Ltd. (the “Company”) on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nan Wang, Chief Financial Officer of the Company, certify, pursuan |
|
| April 29, 2022 |
CEO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weidong Yin, certify that: 1.I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements mad |
|
| April 29, 2022 |
EX-15.2 8 sva-ex1521415.htm EX-15.2 Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We have issued our reports dated April 29, 2022, with respect to the consolidated financial statements and internal control over financial reporting included in the Annual Report of Sinovac Biotech Ltd. on Form 20-F for the year ended December 31, 2021. We consent to the incorporation by refer |
|
| April 29, 2022 |
CFO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Nan Wang, certify that: 1.I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission file number: 001-32371 SINOVAC BIOTECH LTD. |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| February 22, 2022 |
Sinovac Amends Shareholder Rights Plan EX-99.1 3 tm227283d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Sinovac Amends Shareholder Rights Plan BEIJING, February 22, 2022 /PRNewswire/ - Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A Amendment No. 3 FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 SINOVAC BIOTECH LTD. (Exact name of registrant as specified in its charter) Antigua, West Indies Not Applicable (State or other jurisdiction of incorporation or organization) (I.R |
|
| February 22, 2022 |
Exhibit 4.1 SINOVAC BIOTECH LTD. and PACIFIC STOCK TRANSFER COMPANY as Rights Agent THIRD AMENDMENT TO AMENDED AND RESTATED RIGHTS AGREEMENT Effective as of February 21, 2022 This Third Amendment (this ?Amendment?) to the Amended and Restated Rights Agreement (as defined below), is between Sinovac Biotech Ltd., an Antigua and Barbuda company (the ?Company?), and Pacific Stock Transfer Company (the |
|
| December 30, 2021 |
SINOVAC Reports Unaudited First Half of 2021 Financial Results Exhibit 99.1 SINOVAC Reports Unaudited First Half of 2021 Financial Results BEIJING, China, December 30, 2021 /Business Wire/ - Sinovac Biotech Ltd. (NASDAQ: SVA) (?SINOVAC? or the ?Company?), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2021. First Half of 2021 Financial Summary ? Sales for the six mon |
|
| December 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| December 13, 2021 |
6-K 1 tm2135252d16k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 100085, People’s Republic of China (Address of |
|
| December 10, 2021 |
Exhibit 99.1 Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment Current SINOVAC Directors Elected Properly at the 2018 Annual General Meeting The Company?s Rights Agreement is Valid under Antigua Law December 9, 2021 - BEIJING-SINOVAC Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today provided an update fo |
|
| December 10, 2021 |
6-K 1 tm2135132d16k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 100085, People’s Republic of China (Address of |
|
| December 7, 2021 |
SINOVAC Beijing Settled Litigation of Its Business License and Seals Exhibit 99.1 SINOVAC Beijing Settled Litigation of Its Business License and Seals BEIJING, December 3, 2021-SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced the Company?s subsidiary SINOVAC Biotech Co., Ltd ("SINOVAC Beijing") settled the litigation with Mr. Aihua Pan concerning its business license and seals. As |
|
| December 7, 2021 |
6-K 1 tm2134781d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 10085, People’s Republic of China (Address of |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| November 10, 2021 |
Exhibit 99.1 Preliminary Results Show SINOVAC?s COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population BEIJING, China, November 9, 2021 - SINOVAC Biotech Ltd. (NASDAQ: SVA) (?SINOVAC? or the ?Company?), a leading provider of biopharmaceutical products in China, announced new preliminary data on its inactivated COVID-19 vaccine CoronaVac?. The results from s |
|
| July 20, 2021 |
Exhibit 99.1 SINOVAC?s CoronaVac Used on Child Population in China, Good Antibody Levels Observed After Three Months Following Vaccination BEIJING, China, July 19, 2021 - SINOVAC Biotech Ltd. (NASDAQ: SVA) (?SINOVAC? or the ?Company?), a leading provider of biopharmaceutical products in China, today announced CoronaVac, SINOVAC?s COVID-19 vaccine, has started being used among the child population |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| July 20, 2021 |
Exhibit 99.1 SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine (sIPV) to Support Global Polio Endgame Strategy BEIJING, China, July 19, 2021 - SINOVAC Biotech Ltd. (NASDAQ: SVA) (?SINOVAC? or the ?Company?), a leading provider of biopharmaceutical products in China, today announced it received a drug registration approval from the National Medical Product Administration of |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| July 12, 2021 |
6-K 1 tm2121973d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 10085, People’s Republic of China (Address of prin |
|
| July 12, 2021 |
SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX Exhibit 99.1 SINOVAC Enters Into Agreement to Supply CoronaVac? to COVAX BEIJING, China, July 12, 2021 - SINOVAC Biotech Ltd. (NASDAQ: SVA) (?Sinovac? or the ?Company?), a leading provider of biopharmaceutical products in China, announced today that it had signed an advance purchase agreement (APA) with Gavi, the Vaccine Alliance (Gavi), which is on behalf of COVAX Facility, to provide up to 380 m |
|
| June 30, 2021 |
Exhibit 99.1 The Lancet Infectious Diseases Published Data from Sinovac?s Phase I/II Study, World?s First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years Old - CoronaVac? is safe among the pediatric group aged 3 to 17 years old - CoronaVac can induce strong antibody responses in this pediatric group BEIJING, China, June 30, 202 |
|
| June 30, 2021 |
6-K 1 tm2121133d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 100085, People’s Republic of China (Address of pri |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| June 2, 2021 |
World Health Organization Authorizes SINOVAC’s CoronaVac® for Emergency Use Exhibit 99.1 World Health Organization Authorizes SINOVAC?s CoronaVac? for Emergency Use BEIJING-SINOVAC Biotech Ltd. (?SINOVAC? or the ?Company?) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that CoronaVac?, an innovative, inactivated coronavirus vaccine developed by SINOVAC Life Sciences Co., Ltd. (?SINOVAC?), a subsidiary of the Company, was approved |
|
| April 23, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2021 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| April 23, 2021 |
Exhibit 99.1 Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F BEIJING, China, April 22, 2021 /Business Wire/ ? Sinovac Biotech Ltd. (NASDAQ: SVA) (?Sinovac? or the ?Company?), a leading provider of biopharmaceutical products in China, has filed its 2020 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year |
|
| April 22, 2021 |
CEO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weidong Yin, certify that: 1.I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements mad |
|
| April 22, 2021 |
CFO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Nan Wang, certify that: 1.I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the ?Company?); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| April 22, 2021 |
Consent of Marcum Bernstein & Pinchuk LLP EX-15.1 11 sva-ex15113.htm EX-15.1 Exhibit 15.1 Independent Registered Public Accounting Firm’s Consent We consent to the incorporation by reference in this Registration Statement of Sinovac Biotech Ltd. on Form S-8 (FILE NO. 333-161827) and Form S-8 (FILE NO. 333-190980) of our report dated April 22, 2021, with respect to our audits of the consolidated financial statements of Sinovac Biotech Ltd. |
|
| April 22, 2021 |
CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Sinovac Biotech Ltd. (the “Company”) on Form 20-F for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Weidong Yin, Chief Executive Officer of the Company, certify, purs |
|
| April 22, 2021 |
CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Sinovac Biotech Ltd. (the “Company”) on Form 20-F for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nan Wang, Chief Financial Officer of the Company, certify, pursuan |
|
| April 22, 2021 |
Exhibit 2.1 SPECIMEN * NOT VALID UNLESS COUNTERSIGNED BY TRANSFER AGENT * INCORPORATED UNDER THE LAWS OF THE GOVERNMENT OF ANTIGUA Number Sinovac Shares BIOTECH LTD. This Certifies that Is the Owner of Fully paid and non-assessable shares of Common Stock of Sinovac Biotech Ltd. transferable on the books of the Corporation in person or by attorney upon surrender of this certificate duly endorsed or |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission file number: 001-32371 SINOVAC BIOTECH LTD. |
|
| April 22, 2021 |
Exhibit 4.21 SHAREHOLDERS? AGREEMENT This Shareholders? Agreement (this ?Agreement?) is made and entered into by and among the following parties on December 4, 2020 (the ?Execution Date?): 1. Sinovac Life Sciences Co., Ltd. (the ?Company?), a limited liability company validly incorporated and duly existing under the PRC laws with its registered address at Building 1, No. 21 Tianfu Street, Zhonggua |
|
| April 22, 2021 |
Exhibit 2.2 SPECIMEN sinovac biotech, ltd NUMBER incorporated under the laws of the government of antigua not valid unless countersigned by transfer agent SHARES This certifies that is the record holder of FULLY PAID AND NON-ASSESSABLE SHARES OF PREFERRED SERIES ?B? STOCK OF SINOVAC BIOTECH, LTD transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of |
|
| April 22, 2021 |
Exhibit 2.3 Description of Rights of Each Class of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (the ?Exchange Act?) Sinovac Biotech Ltd. (the ?Company?) is an Antiguan company (Company No. 11949) with limited liability and its affairs are governed by its articles of incorporation and by-laws and the International Business Corporations Act. Prior to February 22, 20 |
|
| April 2, 2021 |
Current Report of Foreign Issuer - FORM 6-K 6-K 1 tm2112014d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2021 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 10085, People’s Republic of China (Address of pri |
|
| April 2, 2021 |
Sinovac Announced Buildup of Two Billion Annual Capacity of Its COVID-19 Vaccine Exhibit 99.1 Sinovac Announced Buildup of Two Billion Annual Capacity of Its COVID-19 Vaccine BEIJING, April 1, 2021-Sinovac Biotech Ltd. (?Sinovac? or the ?Company?) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the third production line of CoronaVac?, its COVID-19 vaccine, was completed and put into commercial production. Including this new produc |
|
| February 22, 2021 |
8-A12B/A 1 tm217258d18a12ba.htm 8-A12B/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A Amendment No. 2 FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 SINOVAC BIOTECH LTD. (Exact name of registrant as specified in its charter) Antigua, West Indies Not Applicable (State or other jurisdicti |
|
| February 22, 2021 |
Sinovac Amends Shareholder Rights Plan Exhibit 99.1 Sinovac Amends Shareholder Rights Plan BEIJING, February 22, 2021 /PRNewswire/ - Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2021 to February 22, 2022 |
|
| February 22, 2021 |
Exhibit 4.1 SINOVAC BIOTECH LTD. and PACIFIC STOCK TRANSFER COMPANY as Rights Agent SECOND AMENDMENT TO AMENDED AND RESTATED RIGHTS AGREEMENT Effective as of February 21, 2021 This Second Amendment (this ?Amendment?) to the Amended and Restated Rights Agreement (as defined below), is between Sinovac Biotech Ltd., an Antigua and Barbuda company (the ?Company?), and Pacific Stock Transfer Company (t |
|
| February 22, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| February 8, 2021 |
Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine EX-99.3 4 tm215704d1ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine BEIJING, February 8, 2021-(BUSINESS WIRE)-Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the China National Medical Products Administration (NMPA) has granted |
|
| February 8, 2021 |
Current Report of Foreign Issuer - FORM 6-K 6-K 1 tm215704d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. No. 15 Zhi Tong Road Zhongguancun Science and Technology Park Changping District Beijing 1 |
|
| February 8, 2021 |
Sinovac Files for Conditional Market Authorization of COVID-19 Vaccine in China Exhibit 99.1 Sinovac Files for Conditional Market Authorization of COVID-19 Vaccine in China BEIJING, February 3, 2021—(BUSINESS WIRE)-Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has officially filed for conditional market authorization for CoronaVac, the COVID-19 vaccine, with China’s National |
|
| February 8, 2021 |
Sinovac Announces Phase III Results of Its COVID-19 Vaccine EX-99.2 3 tm215704d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Sinovac Announces Phase III Results of Its COVID-19 Vaccine BEIJING, February 5, 2021—(BUSINESS WIRE)-Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced phase III results. Sinovac had started its phase III trials on CoronaVac, its COVID-19 vaccine, on Ju |
|
| December 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.)* Sinovac Biotech Ltd. (Name of Issuer) Common Shares, $0.001 par value per share (Title of Class of Securities) P8696W104 (CUSIP Number) Quan Li CDH Utopia Limited One Temasek Avenue #18-02, Millenia Tower, Singapore 039192 (+65) 65728750 (Name, Address and |
|
| December 22, 2020 |
EX-99.D 5 tm2038785d1ex99-d.htm EXHIBIT D Exhibit D December 18, 2020 1Globe Biomedical (Hong Kong) Company Limited 8F, Block B, Techart Plaza, No.30 Xueyuan Road, Haidian District, Beijing, 100083, P.R. China Attention: Stella Wang Subject: Amendment to the Letter Agreement Regarding the Proposed Investment by CDH Dear Sir and/or Madam: Reference is made to (i) the share purchase agreement, dated |
|
| December 22, 2020 |
EXHIBIT B SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT (this “Agreement”) dated as of November 24, 2020 is made by and between CDH Utopia Limited, a company incorporated and existing under the laws of the Cayman Islands (the “Purchaser”), and 1Globe Biomedical (Hong Kong) Company Limited, a company incorporated under the laws of Hong Kong (the “Seller”). |
|
| December 22, 2020 |
Exhibit C Strictly Confidential November 24, 2020 1Globe Biomedical (Hong Kong) Company Limited 8F, Block B, Techart Plaza, No. |
|
| December 22, 2020 |
EXHIBIT A JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned acknowledges and agrees that the foregoing statement on this Schedule 13D is filed on behalf of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| December 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* SINOVAC BIOTECH LTD. (Name of Issuer) Common Shares, par value $0.001 per share (Title of Class of Securities) P8696W104 (CUSIP Number) 1Globe Capital LLC One International Place, 44th Fl Boston, MA 02110 617-649-1157 (Name, Address and Telephone Number |
|
| December 21, 2020 |
Exhibit 99.1 SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT (this “Agreement”) dated as of November 24, 2020 is made by and between CDH Utopia Limited, a company incorporated and existing under the laws of the Cayman Islands (the “Purchaser”), and 1Globe Biomedical (Hong Kong) Company Limited, a company incorporated under the laws of Hong Kong (the “Seller”). The Purchaser and the Seller a |
|
| December 21, 2020 |
EX-99.2 3 ex992.htm EXHIBIT 99.2 Exhibit 99.2 Strictly Confidential November 24, 2020 1Globe Biomedical (Hong Kong) Company Limited 8F, Block B, Techart Plaza, No.30 Xueyuan Road, Haidian District, Beijing, 100083, P.R. China Attention: Stella Wang Subject: Letter Agreement Regarding the Proposed Investment by CDH Dear Sir and/or Madam: Reference is hereby made to the share purchase agreement, dat |
|
| December 21, 2020 |
Exhibit 99.3 Strictly Confidential December 18, 2020 1Globe Biomedical (Hong Kong) Company Limited 8F, Block B, Techart Plaza, No.30 Xueyuan Road, Haidian District, Beijing, 100083, P.R. China Attention: Stella Wang Subject: Amendment to the Letter Agreement Regarding the Proposed Investment by CDH Dear Sir and/or Madam: Reference is made to (i) the share purchase agreement, dated as of November 2 |
|
| December 9, 2020 |
Sinovac Announces Product License for 23-Valent Pneumococcal Polysaccharide Vaccine EX-99.1 2 tm2038089d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Sinovac Announces Product License for 23-Valent Pneumococcal Polysaccharide Vaccine BEIJING, December 9, 2020-(BUSINESS WIRE)-Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the China National Medical Products Administration (NMPA) has approved a |
|
| December 9, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2020 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. |
|
| December 7, 2020 |
Sinovac Secures Approximately $500 Million in Funding for COVID-19 Vaccine Development EX-99.1 2 tm2037838d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Sinovac Secures Approximately $500 Million in Funding for COVID-19 Vaccine Development BEIJING, December 7, 2020 - (BUSINESS WIRE) - Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that Sinovac Life Sciences Co., Ltd. (“Sinovac LS”) (formerly known a |
|
| December 7, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2020 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. |
|
| December 7, 2020 |
Sinovac Reports Unaudited Third Quarter 2020 Financial Results Exhibit 99.2 Sinovac Reports Unaudited Third Quarter 2020 Financial Results BEIJING, China, December 7, 2020 / Business Wire / - Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the third quarter ended September 30, 2020. Third Quarter and Nine Months Ended 2020 Financial |
|
| September 29, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2020 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. |
|
| September 29, 2020 |
EX-99.1 2 tm2031987d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Beijing Fourth Intermediate People’s Court Issues Judgement Against Sinobioway Medicine and Mr. Aihua Pan BEIJING, September 28, 2020 - (BUSINESS WIRE) - Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that the Fourth Intermediate People’s Court of Be |
|
| September 23, 2020 |
Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey Exhibit 99.1 Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey BEIJING, China, September 22, 2020 -(BUSINESS WIRE)-Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it has recently commenced phase III clinical trials for its inactivated COVID-19 vaccine candidate develo |
|
| September 23, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2020 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. |
|
| September 23, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2020 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. |
|
| September 23, 2020 |
Exhibit 99.1 Sinovac’s Coronavac, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children BEIJING, China, September 23, 2020 /Business Wire/ - Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that the inactivated COVID-19 vaccine candidate dev |
|
| August 28, 2020 |
Sinovac Reports Unaudited Second Quarter 2020 Financial Results Exhibit 99.1 Sinovac Reports Unaudited Second Quarter 2020 Financial Results BEIJING-(BUSINESS WIRE)- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the second quarter ended June 30, 2020. Second Quarter and First Half of 2020 Financial Summary • Sales for the second qua |
|
| August 28, 2020 |
Current Report of Foreign Issuer - FORM 6-K 6-K 1 tm2029825d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2020 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 10085, People’s Republic of China (Address o |
|
| August 26, 2020 |
Sinovac Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation Exhibit 99.1 Sinovac Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation BEIJING, China – August 25, 2020 - Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it has signed two agreements in Hainan, China with PT Bio Farma, a leading biopharmaceutical company in Indonesia, for the supply, |
|
| August 26, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2020 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. |
|
| July 6, 2020 |
EX-99.1 2 tm2024136d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Sinovac COVID-19 Vaccine Collaboration with Butantan Receives Approval from Brazilian Regulator for Phase III Trial Beijing-July 6, 2020 — Sinovac Biotech Ltd. ( “Sinovac” or the “ Company”)(Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced an update to its previously announced partnership with Butanta |
|
| July 6, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2020 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. |
|
| June 30, 2020 |
Sinovac Reports Unaudited First Quarter 2020 Financial Results Exhibit 99.1 Sinovac Reports Unaudited First Quarter 2020 Financial Results BEIJING, China, June 30, 2020 / Business Wire/ - Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the first quarter ended March 31, 2020. First Quarter of 2020 Financial Summary Ÿ Sales for the fir |
|
| June 30, 2020 |
Current Report of Foreign Issuer - 6-K 6-K 1 tm2023782d16k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2020 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 10085, People’s Republic of China (Address of princ |
|
| June 24, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2020 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| June 24, 2020 |
Sinovac Receives Approval from China for its Quadrivalent Influenza Vaccine Exhibit 99.1 Sinovac Receives Approval from China for its Quadrivalent Influenza Vaccine BEIJING — (BUSINESS WIRE) — Sinovac Biotech Ltd. (“Sinovac” or the “Company”)(Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced the China National Medical Products Administration (or NMPA) issued a product license for its quadrivalent Influenza vaccine (or QIV). Sinovac e |
|
| June 15, 2020 |
Exhibit 99.1 Sinovac Announces Positive Preliminary Results of Phase I/II Clinical Trials for Inactivated Vaccine Candidate Against COVID-19 Beijing-June 13, 2020 — Sinovac Biotech Ltd. (“Sinovac” or the “ Company”)(Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced positive preliminary results of phase I/II clinical trial for the Company’s COVID-19 vaccine ca |
|
| June 15, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2020 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. |
|
| June 11, 2020 |
Exhibit 99.1 Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III Beijing (China), Sao Paulo, (Brazil), June 11th, 2020 – Sinovac Biotech Ltd., (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, and Instituto Butantan, a leading Brazilian producer of immunobiologic products, tod |
|
| June 11, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2020 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. |
|
| May 22, 2020 |
Current Report of Foreign Issuer - 6-K 6-K 1 tm2020769-16k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2020 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China (Address of prin |
|
| May 22, 2020 |
Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development EX-99.1 2 tm2020769d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development BEIJING, May 22, 2020 - (BUSINESS WIRE) - Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced a transaction in which Advantech Capital and Vivo Capital have invested $15 mi |
|
| May 18, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2020 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. |
|
| May 18, 2020 |
Exhibit 99.1 Sinovac Comments on SEC Findings Against Jiaqiang "Chiang" Li and 1Globe Capital SEC Order found Li and 1Globe Violated SEC Rules and Federal Securities Laws by Failing to Disclose Key Facts regarding their Holdings of Sinovac BEIJING, May 18, 2020 - (BUSINESS WIRE) - Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in Ch |
|
| May 6, 2020 |
Current Report of Foreign Issuer - 6-K 6-K 1 tm2018799d16k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2020 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 10085, People’s Republic of China (Address of princi |
|
| May 6, 2020 |
Exhibit 99.1 Sinovac Announces First Animal Study Results of Vaccine Against COVID-19 Published in SCIENCE - Inactivated vaccine for SARS-CoV-2 shows good safety and efficacy on Rhesus Macaques BEIJING, China, May 6, 2020 /Business Wire/ - Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today the publication of t |
|
| April 30, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. |
|
| April 30, 2020 |
CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Sinovac Biotech Ltd. (the “Company”) on Form 20-F for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nan Wang, Chief Financial Officer of the Company, certify, pursuan |
|
| April 30, 2020 |
Consent of Marcum Bernstein & Pinchuk LLP Exhibit 15.1 Independent Registered Public Accounting Firm’s Consent We consent to the incorporation by reference in the Registration Statement of Sinovac Biotech Ltd. on Form S-8 (FILE NO. 333-161827) and Form S-8 (FILE NO. 333-190980) of our report dated April 30, 2020, with respect to our audit of the consolidated financial statements of Sinovac Biotech Ltd. as of December 31, 2019 and for the |
|
| April 30, 2020 |
CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 13.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Sinovac Biotech Ltd. (the “Company”) on Form 20-F for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Weidong Yin, Chief Executive Officer of the Company, certify, purs |
|
| April 30, 2020 |
Exhibit 99.1 Sinovac Reports Unaudited Fourth Quarter 2019 Financial Results and Files 2019 Annual Report on Form 20-F BEIJING, China, April 30, 2020 /Business Wire/ - Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2019 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year |
|
| April 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission file number: 001-32371 SINOVAC BIOTECH LTD. |
|
| April 30, 2020 |
Specimen of Series B Convertible Preferred Shares Exhibit 2.2 SPECIMEN sinovac biotech, ltd NUMBER incorporated under the laws of the government of antigua not valid unless countersigned by transfer agent SHARES This certifies that is the record holder of FULLY PAID AND NON-ASSESSABLE SHARES OF PREFERRED SERIES “B” STOCK OF SINOVAC BIOTECH, LTD transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of |
|
| April 30, 2020 |
CEO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weidong Yin, certify that: 1.I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements mad |
|
| April 30, 2020 |
Consent of Ernst & Young Hua Ming LLP Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: i) Registration Statement (Form S-8 No. 333-161827) pertaining to Sinovac Biotech Ltd.’s 2003 Stock Option Plan; and ii) Registration Statement (Form S-8 No. 333-190980) pertaining to Sinovac Biotech Ltd.’s 2012 Share Incentive Plan; of our re |
|
| April 30, 2020 |
Specimen of Common Share Certificate Exhibit 2.1 SPECIMEN * NOT VALID UNLESS COUNTERSIGNED BY TRANSFER AGENT * INCORPORATED UNDER THE LAWS OF THE GOVERNMENT OF ANTIGUA Number Sinovac Shares BIOTECH LTD. This Certifies that Is the Owner of Fully paid and non-assessable shares of Common Stock of Sinovac Biotech Ltd. transferable on the books of the Corporation in person or by attorney upon surrender of this certificate duly endorsed or |
|
| April 30, 2020 |
Exhibit 2.3 Description of Rights of Each Class of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”) Sinovac Biotech Ltd. (the “Company”) is an Antiguan company (Company No. 11949) with limited liability and its affairs are governed by its articles of incorporation and by-laws and the International Business Corporations Act. Prior to February 22, 20 |
|
| April 30, 2020 |
CFO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Nan Wang, certify that: 1.I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| April 17, 2020 |
SVA / Sinovac Biotech Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. |
|
| April 17, 2020 |
EX-99.1 2 tm2016203d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19 BEIJING -(BUSINESS WIRE)- April 17, 2020- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company has commenced Phase I clinical trial, a ra |
|
| April 14, 2020 |
Sinovac Announces Approval of Human Clinical Trial for a Vaccine Candidate Against COVID-19 Exhibit 99.1 Sinovac Announces Approval of Human Clinical Trial for a Vaccine Candidate Against COVID-19 BEIJING-(BUSINESS WIRE)- April 14, 2020- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company has obtained approval to conduct a human clinical trial on an inactivated SARS-CoV-2 (commonly ref |
|
| April 14, 2020 |
SVA / Sinovac Biotech Ltd. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2020 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. |
|
| February 21, 2020 |
Sinovac Amends Shareholder Rights Plan Exhibit 99.1 Sinovac Amends Shareholder Rights Plan BEIJING, February 21, 2020 /PRNewswire/ - Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2020 to February 22, 2021 |
|
| February 21, 2020 |
Exhibit 4.1 SINOVAC BIOTECH LTD. and PACIFIC STOCK TRANSFER COMPANY as Rights Agent AMENDMENT TO AMENDED AND RESTATED RIGHTS AGREEMENT Effective as of February 19, 2020 This Amendment (this “Amendment”), dated as of February 19, 2020 to the Amended and Restated Rights Agreement, dated as of February 22, 2019 (the “Amended and Restated Rights Agreement”), is between Sinovac Biotech Ltd., an Antigua |
|
| February 21, 2020 |
SVA / Sinovac Biotech Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2020 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. |
|
| February 21, 2020 |
SVA / Sinovac Biotech Ltd. 8-A12B/A - - 8-A12B/A 8-A12B/A 1 tm209518d28a12ba.htm 8-A12B/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A Amendment No. 1 FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 SINOVAC BIOTECH LTD. (Exact name of registrant as specified in its charter) Antigua, West Indies Not Applicable (State or other jurisdicti |
|
| December 31, 2019 |
EX-99.1 2 tm1928301d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Sinovac Announces Approval of Varicella Vaccine for Prevention of Varicella-Zoster Virus (Chickenpox) in Children BEIJING, December 27, 2019-Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the China National Medical Products Administration (NMPA) |
|
| December 31, 2019 |
SVA / Sinovac Biotech Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2019 - Commission File Number: 001-32371 - SINOVAC BIOTECH LTD. |
